Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 38,766 | 104,112 | 148,657 | 52,280 | 51,677 |
| Cost of Goods | 12,347 | 8,218 | 20,950 | 8,041 | 14,098 |
| Gross Profit | 26,420 | 95,895 | 127,707 | 44,239 | 37,580 |
| Operating Expenses | 170,271 | 149,469 | 167,599 | 190,569 | 191,247 |
| Operating Income | -143,505 | -53,357 | -38,942 | -146,289 | -153,570 |
| Interest Expense | 21,133 | 83,774 | 265 | 26,687 | 10,178 |
| Other Income | 47,093 | -2,411 | -47,556 | -2,886 | 30,869 |
| Pre-tax Income | -117,545 | -139,542 | -86,763 | -175,862 | -132,878 |
| Income Tax | 247 | 2,723 | 6,278 | 702 | -468 |
| Net Income Continuous | -117,791 | -142,265 | -93,041 | -176,564 | -132,411 |
| Net Income | $-117,791 | $-142,265 | $-93,041 | $-176,564 | $-132,411 |
| EPS Basic Total Ops | -2.06 | -2.50 | -1.64 | -3.14 | -2.36 |
| EPS Basic Continuous Ops | -2.05 | -2.50 | -1.64 | -3.14 | -2.36 |
| EPS Diluted Total Ops | -2.06 | -2.50 | -1.64 | -3.14 | -2.36 |
| EPS Diluted Continuous Ops | -2.05 | -2.50 | -1.64 | -3.14 | -2.36 |
| EPS Diluted Before Non-Recurring Items | -2.05 | -2.48 | -1.66 | -3.12 | N/A |
| EBITDA(a) | $-138,818 | $-48,496 | $-33,641 | $-141,145 | $-148,428 |